163 related articles for article (PubMed ID: 36228178)
21. Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
Konuma T; Harada K; Yamasaki S; Mizuno S; Uchida N; Takahashi S; Onizuka M; Nakamae H; Hidaka M; Fukuda T; Ohashi K; Kohno A; Matsushita A; Kanamori H; Ashida T; Kanda J; Atsuta Y; Yano S;
Am J Hematol; 2019 Jan; 94(1):103-110. PubMed ID: 30370944
[TBL] [Abstract][Full Text] [Related]
22. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
23. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
24. Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.
Cao W; Li X; Zhang R; Bian Z; Zhang S; Li L; Xing H; Liu C; Xie X; Jiang Z; Fang X; Wan D; Yu J
Sci Rep; 2022 Nov; 12(1):19024. PubMed ID: 36347881
[TBL] [Abstract][Full Text] [Related]
25. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
26. Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR.
Novitzky-Basso I; Chen C; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law A; Al-Shaibani Z; Gerbitz A; Pasic I; Mattsson J; Michelis FV
Eur J Haematol; 2021 Sep; 107(3):354-363. PubMed ID: 34076909
[TBL] [Abstract][Full Text] [Related]
27. Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2017 Dec; 30(4):320-326. PubMed ID: 29156203
[TBL] [Abstract][Full Text] [Related]
28. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics.
Yamasaki S; Mizuno S; Iwasaki M; Seo S; Uchida N; Shigesaburo M; Nakano N; Ishiwata K; Uehara Y; Eto T; Takase K; Kawakita T; Tanaka M; Sawa M; Katayama Y; Nawa Y; Makoto O; Ichinohe T; Atsuta Y; Kanda J; Yanada M
Ann Hematol; 2023 Jun; 102(6):1549-1559. PubMed ID: 37126115
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
31. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
32. Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study.
Bhatt VR; Chen B; Lee SJ
Bone Marrow Transplant; 2018 Jul; 53(7):873-879. PubMed ID: 29403021
[TBL] [Abstract][Full Text] [Related]
33. Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era.
Appelbaum FR
Am Soc Clin Oncol Educ Book; 2014; ():e327-33. PubMed ID: 24857121
[TBL] [Abstract][Full Text] [Related]
34. The National Marrow Donor Program: improving access to hematopoietic cell transplantation.
Walker T; Milford E; Chell J; Maiers M; Confer D
Clin Transpl; 2011; ():55-62. PubMed ID: 22755401
[TBL] [Abstract][Full Text] [Related]
35. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
37. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
Bonafede M; Anaissie E; Evans K; Itzler R
BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
[TBL] [Abstract][Full Text] [Related]
38. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.
Eapen M; Rubinstein P; Zhang MJ; Camitta BM; Stevens C; Cairo MS; Davies SM; Doyle JJ; Kurtzberg J; Pulsipher MA; Ortega JJ; Scaradavou A; Horowitz MM; Wagner JE
J Clin Oncol; 2006 Jan; 24(1):145-51. PubMed ID: 16382124
[TBL] [Abstract][Full Text] [Related]
39. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.
Mawad R; Gooley TA; Sandhu V; Lionberger J; Scott B; Sandmaier BM; O'Donnell P; Becker PS; Petersdorf S; Dorcy KS; Hendrie P; Sorror ML; Walter RB; Deeg HJ; Appelbaum FR; Estey EH; Pagel JM
J Clin Oncol; 2013 Nov; 31(31):3883-8. PubMed ID: 24062388
[TBL] [Abstract][Full Text] [Related]
40. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
Kharfan-Dabaja MA; Labopin M; Brissot E; Kroger N; Finke J; Ciceri F; Deconinck E; Blaise D; Chevallier P; Gramatzki M; Ganser A; Stelljes M; Edinger M; Savani B; Ruggeri A; Sanz J; Nagler A; Mohty M
Br J Haematol; 2021 May; 193(3):592-601. PubMed ID: 33838047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
